What does AI pharmaceuticals still lack before a market explosion? | Focus

① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.

cls.cnJan 20 08:34

Kontafarma China Extends Tenancy Agreement With SPF Until 2027

MT NewswiresDec 26, 2024 14:12

Konta China (01312) subsidiary company obtained temporary stay of winding-up petition pending Hong Kong legal proceedings from the Grand Court of Cayman Islands.

金吾财讯 | konta china Corporation (01312) announced that the Cayman Islands court issued a judgment last Thursday (3rd) on the application made by its subsidiary Fester Global, which aims to revoke or reject or wait for the ruling of the 2019 Hong Kong legal procedures and the 2021 Hong Kong legal procedures in 2024. According to the Cayman judgment, the Cayman court granted a temporary stay of case management for the 2024 Cayman petition, pending the ruling of the Hong Kong procedures. The group pointed out that the 2024 Cayman petition involves Active Gains Universal.

Golden Guard Financial NewsOct 8, 2024 09:09

Cayman Court Grants Temporary Stay in Winding-Up Proceedings Against Kontafarma China Unit

MT NewswiresOct 7, 2024 20:23

KONTA CHINA: 2024 INTERIM REPORT

HKEXSep 26, 2024 18:33 · Announcements

《Performance》Konta China (01312.HK) reported a net profit of 4.75 million yuan in the first half of the year, a decrease of 87.9%, and no dividend will be distributed.

Konta China (01312.HK) announced its interim results for the six months ending in June, with revenue of 0.459 billion yuan, a year-on-year increase of 6.5%. It recorded a net profit of 4.75 million yuan, a decrease of 87.9%, with earnings per share of 0.09 cents. No interim dividend will be distributed.

AASTOCKSAug 29, 2024 02:05